A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) or B-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2014
At a glance
- Drugs GNKG 168 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Biomarker
- Sponsors SBI Biotech
- 18 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Jul 2012 Official title amended as reported by Oregon Health and Science University Institutional Review Board.
- 21 Mar 2012 New source identified and integrated (IRB00006550; Oregon Health and Science University Institutional Review Board).